Biochemical and morphological analyses confirmed that treatment of HeLa cells with a novel KSP inhibitor in combination with PI3K/AKT/mTOR inhibitors resulted in potentiated cell death over the treatment of these small molecules individually (Figure 1; Supplementary Figures S1, S2), supporting earlier results that PI3K inhibitors sensitize cancer cells to antimitotic drugs (Hou et al., 2012). This evidence concerns the gene AKT1 and cancer.